Comparative Pharmacology
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus JESDUVROQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus JESDUVROQ.
DICYCLOMINE HYDROCHLORIDE vs JESDUVROQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
JESDUVROQ is a small molecule inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6, blocking retinoblastoma protein phosphorylation and inducing G1 cell cycle arrest.
10-20 mg orally 3-4 times daily
IV: 10 mg/kg every 4 weeks, infused over 60 minutes.
None Documented
None Documented
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Terminal elimination half-life is 12-15 hours in patients with normal renal function (CrCl >90 mL/min). Half-life increases with renal impairment (up to >30 hours in end-stage renal disease), requiring dose adjustment.
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Primarily renal elimination (70-80% unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal excretion accounts for 15-20% as metabolites, with less than 5% unchanged in feces.
Category A/B
Category C
Anticholinergic
Anticholinergic